Dark

Check out our Dark Pool Levels

BCYP
Big Cypress Acquisition Corp. Common stock
stock NASDAQ

Inactive

Oct 25, 2021

7.30USD-13.507%(-1.14)572,739

Pre-market

0.00USD-100.000%(-8.44)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Oct 25, 2021

07:40AM EDT SAB Biotherapeutics Debuts as Publicly Traded Next-Generation GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Big Cypress Acquisition Corp. Stockholders Approve Business Combination With SAB Biotherapeutics Benzinga

07:01AM EDT Big Cypress Acquisition Corp. Stockholders Approve Business Combination with PR Newswire

Oct 4, 2021

10:25AM EDT Northland Capital Markets Initiates Coverage On Big Cypress Acquisition with Outperform Rating, Announces Price Target of $18 Benzinga

07:03AM EDT Big Cypress Acquisition Merger Partner SAB Biotherapeutics Announces First Patient Dosed In Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 For Treatment Of COVID-19 Benzinga

Oct 1, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021 Benzinga

07:01AM EDT Ladenburg Thalmann Initiates Coverage On Big Cypress Acquisition with Buy Rating, Announces Price Target of $16.5 Benzinga

Sep 24, 2021

07:02AM EDT Big Cypress Acquisition Corp. Merger Partner SAB Biotherapeutics Announces Independent Data Safety Monitoring Board Has Completed Interim Analysis Of SAB-185 In Phase 2 Portion Of ACTIV-2 Trial And Recommended Advancement To Phase 3 Benzinga

Sep 23, 2021

07:14AM EDT Big Cypress Acquisition Reports Special Meeting Of Stockholders To Approve Business Combination With SAB Biotherapeutics RTTNews

07:01AM EDT Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to PR Newswire

Sep 22, 2021

07:02AM EDT SAB Biotherapeutics Awarded Additional $60.5M From BARDA And U.S. Department Of Defense For Rapid Response Capability And Advancing SAB-185 For Treatment Of COVID-19 Benzinga

Sep 15, 2021

07:01AM EDT Big Cypress Acquisition Merger Partner SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza Benzinga

Aug 11, 2021

07:17AM EDT Big Cypress Acquisition Corp. SPAC Merger Partner, SAB Biotherapeutics, Gives Non-Clinical Data Showing SAB-185 Potently Neutralizes Deal, Lambda SARS-CoV-2 Variants Benzinga

Jul 15, 2021

07:03AM EDT Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by PR Newswire

Jul 9, 2021

07:00AM EDT SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 Business Wire

Jul 8, 2021

05:17PM EDT CORRECTION: Big Cypress SPAC Merger Partner, SAB, Issued Preclinical Data On Its SAB-185 This Morning At 7:06 a.m. EDT Benzinga

05:14PM EDT Big Cypress Acquisition Corp. SPAC Merger Partner, SAB Biotherapeutics, Highlights Publication Of Preclinical Data Showing SAB-185 Effectively Neutralizes SARS-CoV-2 Variants Benzinga

07:08AM EDT Big Cypress Acquisition Corp. SPAC Merger Partner SAB Biotherapeutics Highlights Publication Of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants Benzinga

Jul 7, 2021

07:05AM EDT Big Cypress Acquisition Corp. Announces Confidential Submission Of S-4 Registration Statement Related To Proposed Business Combination With SAB Biotherapeutics Benzinga

07:01AM EDT Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics PR Newswire

Jul 2, 2021

07:49AM EDT Big Cypress Acquisition Merger Partner, SAB Biotherapeutics, Reports Dosing Of First Patient In Phase 2a Trial Of SAB-176 For Treatment Of Flu Benzinga

Jun 29, 2021

07:28AM EDT SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza Benzinga

Jun 22, 2021

06:03AM EDT SAB Biotherapeutics To Go Public Through Merger With Big Cypress Acquisition Corp.; Transaction Implies Enterprise Value Of $325M Benzinga

Feb 4, 2021

08:00AM EST Big Cypress Acquisition Corp. Announces Separate Trading of its GlobeNewswire Inc

Jan 14, 2021

12:10PM EST Big Cypress Acquisition Corp. Announces Closing of $115 Million GlobeNewswire Inc

Share